You are here: Industry Insights > Immuno

News List

Personalized Vaccines: How Neoantigens Are Changing Cancer Immunotherapy Nurah Ekhlaque
April 07, 2025
Explore how neoantigen-based vaccines are revolutionizing cancer immunotherapy by enabling personalized, targeted treatment strategies for better outcomes.
Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology Krebs Qin
October 18, 2024
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
Immuno-Oncology: Current Market Landscape and Future Trends（1） Neeta Ratanghayra
September 18, 2024
Immune Checkpoint Inhibitors & Challenges and Future Directions.
Immuno-Oncology: Current Market Landscape and Future Trends（2） Neeta Ratanghayra
September 18, 2024
CAR-T Therapy & Antibody–Drug Conjugates.
Immunoconjugates: Biological Missiles for Diagnosis and Treatment Suzanne Elvidge
August 02, 2024
Immunoconjugates already play an important role in the treatment of cancer, and their role is likely to expand into other therapeutic indications.
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines Daivd Orchard Webb/PharmaSources
July 03, 2023
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
O-drug Approved as First-line Immunotherapy for Gastric Cancer and What Other Domestic Counterparts to Expect PharmaSources/Yefenghong
May 08, 2021
O-drug is the first approved immunotherapy for first-line treatment of gastric cancer.
Pharma Sources Insight April 2021: Towards a Future of Immunotherapy Pharma Sources Insight
May 06, 2021
Pharma Sources Insight April 2021 focuses on the future of Immunotherapy, new developments of the Chinese bio-pharmaceutical industry and more.
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies ACN Newswire
August 02, 2025
Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash.
Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans PRNewswire
June 19, 2025
Immuno Cure and PharmaJet have announced a collaboration to clinically evaluate ICVAX, an innovative HIV therapeutic DNA vaccine, using PharmaJet's needle-free delivery technology.